GlassScriptPhysician profile
Bryan N Martin
NPI 1477198893
$2,357.71
in general payments reported to CMS, 2019-2025
32 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $523 · 2022: $758 · 2023: $415 · 2024: $322 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.91 | 2021-2025 | |
| Astellas Pharma US INC | $275.69 | 2021-2022 | |
| Optinose US, INC. | $234.67 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $163.57 | 2021-2022 | |
| Axonics, INC. | $157.94 | 2021-2022 | |
| Myovant Sciences INC. | $124.71 | 2021 | |
| Orthofix Medical, INC. | $110.59 | 2023 | Spinal-Stim, Spinal-Stim |
| Argenx US, INC. | $87.62 | 2023-2024 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $73.52 | 2023-2024 | Nuedexta |
| Medtronic, INC. | $67.00 | 2022-2025 | Propel, Interstim |
| Pfizer INC. | $65.00 | 2021-2022 | |
| Baxter Healthcare | $63.87 | 2023-2025 | Floseal, Perclot |
| Urovant Sciences INC | $61.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.98 | 2021-2022 | |
| Antares Pharma, INC. | $57.03 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $41.40 | 2024 | Ultomiris |
| Olympus America INC. | $40.36 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $40.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.18 | 2023 | Gammagard |
| Lilly USA, LLC | $37.41 | 2024 | Emgality, Amyvid |
| Boston Scientific Corporation | $35.72 | 2021-2024 | Ams 700 |
| Acorda Therapeutics, INC | $29.56 | 2023 | Inbrija |
| Genentech USA, INC. | $25.76 | 2024 | Ocrevus |
| Clarus Therapeutics INC. | $22.58 | 2021 | |
| Progenics Pharmaceuticals, INC. | $21.02 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $19.96 | 2022 | |
| Csl Behring | $19.47 | 2023 | Kcentra |
| Amgen INC. | $17.51 | 2023 | Aimovig |
| Ucb, INC. | $16.99 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.20 | 2025 | Xhance |
| Convatec INC. | $15.73 | 2021 | |
| Curonix LLC | $13.24 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.